Hepatitis B Virus (HBV) FibroSure®
Also known as: Actitest, FibroSure®, FibroTest
Use
Assessment of liver status following a diagnosis of HBV; baseline determination of liver status before initiating HBV therapy; posttreatment assessment of liver status six months after completion of therapy; noninvasive assessment of liver status in patients who are at increased risk of complications from a liver biopsy
Special Instructions
The patient's age and gender must be included on the test request form.
Limitations
The test is not recommended for patients with Gilbert Disease, acute hemolysis, acute hepatitis of the liver, extra-hepatic cholestasis, transplant patients, and renal insufficiency. It may lead to inaccurate predictions of fibrosis and necroinflammatory activity in these conditions. The negative predictive value for absence of significant fibrosis (score 0.48) is 89% compared to liver biopsy.
Methodology
Other
Biomarkers
LOINC Codes
- 48792-6
- 48793-4
- 48794-2
- 48795-9
- 62364-5
- 1835-8
- 4542-7
- 1869-7
- 1975-2
- 2324-2
- 1743-4
- 77202-0
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3.5 mL
Minimum Volume
2 mL
Container
Gel-barrier tube is preferred. Red top tube is acceptable.
Collection Instructions
Separate serum from cells within two hours of collection, and transfer serum to a transfer tube.
Patient Preparation
Patient should be fasting for at least eight hours.
Storage Instructions
Specimen can be stored refrigerated at 2°C to 8°C for 72 hours and frozen at -70°C for seven days. Frozen samples are stable for one freeze/thaw cycle.
Causes for Rejection
Gross hemolysis; gross lipemia; improper labeling; nonfasting specimen; patient younger than 14 years of age
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 72 hours |
| Frozen | 7 days |